Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2019. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| January 10, 2019 | Ordinary Shares (25p each) | £15.2440 | 16 Shares | London Stock Exchange (XLON) |
Note: Each transaction consisted of 8 partnership shares and 8 matching shares acquired under the Company's Share Reward Plan.
Material Changes
This filing reports routine compliance disclosures regarding share acquisitions by senior management. It does not report material changes to the company's financial position, operations, or strategy compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory notification of share purchases.
Important Facts for Investors
- Insider Activity: Nine senior executives, including CEO Emma Walmsley and CFO Simon Dingemans, acquired shares on the same date.
- Transaction Type: All acquisitions were made under the Company's Share Reward Plan, indicating standard compensation-related activity rather than open-market speculation.
- Volume: The volume per executive was minimal (16 shares each), suggesting these were likely vesting events or matching contributions rather than significant new capital deployment.
- Price: The acquisition price was uniform at £15.2440 per share across all reported transactions.